Tonix Pharmaceuticals Holding (TNXP) Cash & Equivalents (2010 - 2026)

Tonix Pharmaceuticals Holding has reported Cash & Equivalents for 17 years, with the latest figure at $176.2 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 39.61% year-over-year to $176.2 million in Q2 2026; TTM through Jun 2026 was $176.2 million, a 39.61% increase from a year earlier, with the FY2025 full-year figure at $207.6 million, up 108.3% from the prior year.
• Cash & Equivalents was $176.2 million for Q2 2026 at Tonix Pharmaceuticals Holding, down from $185.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $207.6 million in Q4 2025, with the low at $4.2 million in Q2 2024.
• Average Cash & Equivalents over 5 years is $101.8 million, with a median of $123.4 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 95.06% in 2023, then jumped 2937.44% in 2025.
• Over 5 years, Cash & Equivalents stood at $120.5 million in 2022, then sank by 78.54% to $25.8 million in 2023, then jumped by 285.62% to $99.7 million in 2024, then jumped by 108.3% to $207.6 million in 2025, then slipped by 15.12% to $176.2 million in 2026.
• The last three Cash & Equivalents figures came in at $176.2 million (Q2 2026), $185.5 million (Q1 2026), and $207.6 million (Q4 2025), per Business Quant data.